<SEC-DOCUMENT>0001193125-15-190959.txt : 20150518
<SEC-HEADER>0001193125-15-190959.hdr.sgml : 20150518
<ACCEPTANCE-DATETIME>20150518080134
ACCESSION NUMBER:		0001193125-15-190959
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150518
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150518
DATE AS OF CHANGE:		20150518

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDNAX, INC.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				263667538
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		15871875

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d927950d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (date of earliest event reported): May&nbsp;18, 2015 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Florida</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-12111</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>26-3667538</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1301 Concord Terrace</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sunrise, Florida 33323</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive office) (zip code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code <U>(954)&nbsp;384-0175</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;18, 2015, MEDNAX, Inc., a Florida corporation (the &#147;Company&#148;),
issued a press release announcing the completion of the previously announced acquisition of Virtual Radiologic Corporation, a leading radiology physician services and telemedicine company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase consideration for the transaction was $500 million, which includes the assumption of certain net operating loss carryforwards, the cash portion
of which consideration was funded with cash on hand and from the Company&#146;s unsecured revolving credit facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the press release is
attached hereto as Exhibit 99.1. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits.</B> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">99.1&#151; Press Release of MEDNAX, Inc. dated May&nbsp;18, 2015. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"><B>MEDNAX, INC.</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: May 18, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Vivian Lopez-Blanco</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Vivian Lopez-Blanco</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of MEDNAX, Inc. dated May 18, 2015</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d927950dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g927950ex99_1pg01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR MORE INFORMATION: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles Lynch </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Strategy and Investor Relations
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">954-384-0175, x-5692 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>charles_lynch@mednax.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>FOR IMMEDIATE RELEASE</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX
Completes Acquisition of vRad </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Expects Initial Annualized Accretion of $0.10 per Share </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FORT LAUDERDALE, Fla., May&nbsp;18, 2015 &#150; MEDNAX, Inc. (NYSE: MD), the national medical group specializing in neonatal, anesthesia, maternal-fetal,
pediatric cardiology and other pediatric physician services, today announced that it has completed the previously announced acquisition of Virtual Radiologic Corporation (vRad), a leading radiology physician services and telemedicine company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase consideration for the transaction was $500 million, which includes the assumption of certain net operating loss carryforwards.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the Company indicated in its initial announcement of the transaction, the acquisition is expected to be accretive to GAAP earnings.
Based on vRad&#146;s current results, and based on expected annual non-cash depreciation and amortization expense of approximately $20 million, MEDNAX anticipates that the acquisition will add an initial $25 million in annualized operating income
and $0.10 in annualized diluted earnings per share. The Company anticipates that this contribution will increase in the foreseeable future, based on expected percentage growth in organic revenue at vRad in the high single digits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s estimate of expected depreciation and amortization expense is preliminary and remains subject to the completion of a
third-party valuation to determine the fair value of the underlying net assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT vRAD </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">vRad (Virtual Radiologic) is a leading outsourced radiology physician services and telemedicine company with over 350 U.S. board-certified and eligible
physicians, 75% of whom are subspecialty trained. The company interprets over 5&nbsp;million patient studies annually&#151;and </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
processes over 1.2 billion images on what it believes is the world&#146;s biggest and most advanced teleradiology picture archiving and communication system (PACS) &#151; for its 2,100+ client
hospital, health system and radiology group facilities. A winner of Frost&nbsp;&amp; Sullivan&#146;s Visionary Innovation Award for Medical Imaging Analytics (North America) and a leader in imaging analytics, vRad provides access to the only
radiology patient care benchmarking platform (vRad RPC<SUP STYLE="font-size:85%; vertical-align:top">SM</SUP> Index) with 31 million+ normalized imaging studies, growing at approximately 400,000&nbsp;per month. vRad&#146;s clinical expertise and
evidence-based insight help clients make better decisions for the health of their patients and their imaging services. For more information about the company, including vRad&#146;s <U>2014 Frost&nbsp;&amp; Sullivan Best Practices Award</U>, please
visit <U>www.vrad.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT MEDNAX </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX,
Inc. is a national medical group comprised of the nation&#146;s leading providers of neonatal, anesthesia, maternal-fetal and pediatric physician subspecialty services. Physicians and advanced practitioners practicing as part of MEDNAX are reshaping
the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives and clinical research to enhance patient outcomes and provide high-quality, cost-effective care. Pediatrix Medical Group, a
division of MEDNAX, was founded in 1979 and includes neonatal physicians who provide services at more than 370 neonatal intensive care units, and collaborate with affiliated maternal-fetal medicine, pediatric cardiology, pediatric critical care and
other physician subspecialists to provide a clinical care continuum. Pediatrix is also the nation&#146;s largest provider of newborn hearing screens. American Anesthesiology, a division of MEDNAX, was established in 2007 and includes more than 2,400
anesthesiologists and advanced practitioners who provide anesthesia care to patients in connection with surgical and other procedures as well as pain management. MEDNAX, through its affiliated professional corporations, employs more than 2,675
physicians in 34 states and Puerto Rico. In addition to its national physician network, MEDNAX provides services to medical providers in over 40 states through two complementary businesses, consisting of a revenue cycle management company and a
consulting services company. Additional information is available at <U>www.mednax.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating
to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These
statements are often characterized by terminology such as &#147;believe&#148;, &#147;hope&#148;, &#147;may&#148;, &#147;anticipate&#148;, &#147;should&#148;, &#147;intend&#148;, &#147;plan&#148;, &#147;will&#148;, &#147;expect&#148;,
&#147;estimate&#148;, &#147;project&#148;, &#147;positioned&#148;, &#147;strategy&#148; and similar expressions, and are based on assumptions and assessments made by MEDNAX&#146;s management in light of their experience and their perception of
historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and MEDNAX
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in MEDNAX&#146;s most recent Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q, including the sections entitled &#147;Risk Factors&#148;, as well MEDNAX&#146;s current reports on Form 8-K, filed with the Securities and Exchange Commission. In addition, there can be no certainty that
vRad will achieve the forecasted results presented in this press release and forward-looking statements regarding vRad set forth herein are subject to a variety of risks and uncertainties applicable to business acquisitions. These include, without
limitation: whether vRad can be successfully integrated into MEDNAX&#146;s operations; whether vRad will be able to maintain its pre-acquisition revenue or operating income or achieve the projected growth in such results; the effect of any
&nbsp;final valuation of vRad&#146;s assets on MEDNAX&#146;s depreciation and amortization expense; changes in interest rates applicable to MEDNAX&#146;s credit facility; the extent of any unknown or contingent liabilities that vRad may have,
including liabilities for failure to comply with applicable laws, or liabilities relating to medical malpractice claims; and other risks and uncertainties affecting vRad&#146;s business.</I> <I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g927950ex99_1pg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g927950ex99_1pg01.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`'8`T@,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/?:0@H`*`"@`H`*`"@`H`*`"@`H`C,\(E$1E02'D)N&?RI7
M6P[$E,04`5;^^BTZU:>7.`<`#JQ]*3:BKL:5]"KI.M1ZJ9$$1B=.<$YR*F,^
M8J4>4U*L@*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`XZ
M[TV_/B-GCB<[I0ZR#H!GUKG<7S&R:Y3L:Z#$*`,/Q*MM-:+$]U'%*K;E#'KQ
M[5E4LT:0O<H^'[C3+`/YEVIGDXSM(4#TR:F#C'J.2;.I5E=0RD%3T(/6MS(6
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`YGQ-JL\$JV=NYC
M^7<[#J<]JQJ2:T1K"*>IS*SRHVY97#>H8UC=HU.R\.ZH]_;-%.V9HL<_WAZU
MT4Y76IA-69KROY<+O_=4FM"#S:0RS%[A\MN;ECZUQO74ZMM!UM:S7DPA@3?(
M02!G'2A)O1";L;OAK4)8+PZ?,3M;.T-_"P[5K3E9\K(FM+G6UN8A0`4`%`!0
M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`1S7$-N%,TJ1AC@%CC)I-I;C2OL2#D
M9%,1B6MO'=Z]?W4J*R18C7=R`<<_Y]ZS2]YLMNR2.-FV^=)LX3<=OTKG>YLM
MC?M6:QNK;58U_P!$G7;-M_@/?]1FM5HU);$/7W38UR]$=AY$)WSW(VQJG)(/
M4UI-V5D1!:G/:E9_V;I%M;N!Y\KF1_;`P!^M8R7+&QHG=W*6E78LM3AG8X0'
M#?0\&IB^5W*DKJQT6IV:QZ_I]Y%C;-(`V.Y'?\OY5M)6DF91?NM'15J9A0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`<YXH6VF2-6NDCGBR0AR<@_3I
MTK*I9]32%T)I^JEK.#3[$-+<!<&5EPJ#U]\41EIRH;CU9)K=Y#I>G&RMSB:4
M<XZX/5C[FB;459"BKN[./KG-CK_";B33YX6&55\X(XY'_P!:NBEL8U-S:BL[
M:!R\4"(V,9`Z#T'I6EDB+LY#Q`\E[KI@B!8IB-5'K_\`K-83UE8VAI&Y7U+1
M+C3(8Y965U;@E?X3Z5,H.(XR3-_3[M'T>QN9P2EN^UFZ[>"`3^8K:+]U-F;6
MK0_4]9N;>^@MK*%9=X!R>0V3T&*)3:=D$8IJ[-B*>*9G6)P^PX8@Y`/I5IW(
MV)*8@H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`(YVD2!S$NZ3'RCU/:D]AHXK
M7;!;&2#=,TMQ("TK'N<__KKGG&QM%W-7P@Z_9KE,#<'!/KC%:4MB:A/XAT^U
M&FW-V(5^T?+\_.?O`?RIU$K7%!N]C-32(O\`A%FNC'_I&/,#>V>GY5'*N2Y7
M-[UC:\/01QZ1#(B!7D&7([X)Q6E-6B1-ZFK5D',Z#!]JU>\U!^0KD)]3_P#6
M_G6,%>39K+1)&QJ]J+O2IXL?,%W+]1S6DE=$1=F9OA4"32IXG`9/,(P1Z@5%
M+X2IZ,YV9$&KO;0R,D'G;!@]!G%96]ZR-+Z7.\M;6&RMU@@7:B_K[FNE*RLC
M!NY-3$%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!!=3O;PEXX'F?H$3O^/:D]
M!HQ(=$GU"[>\U;C/"Q*>@^HK-0;=Y&G,DK1':-9?V?KE[`A)B"`@GWZ?UHA'
MEDT*3ND7]=0OHMRH&3M!Q]"*J?PLF&C)GM@NDM;8&!#LQCVQ56TL%];B:5'Y
M6DVJ$8/E@G\1FE'1();EF5MD+MZ*35$E+1;0V>E0HP(D;YVSZFI@K(J3NS0Q
MD8-429NB6IL[6:+&`)WQ].@_E405D7)W9E6GAR.YTPR2,R7C,QW9X4@XQC\*
MA4[K4ISLS=L#>"$)>1J)%XWHV0WO6JO;4S=NA:IB"@`H`*`"@`H`*`"@#"\7
M:[+X;\/2ZE!`DSQNJ[')`Y..U5%7=A2=E<\[_P"%RW__`$";?_OXU:>R\S+V
MOD>A^$?$T/BG15O$41SH=DT0.=C?X$5G*/*S2,N9&]4E'F7B+XK'2];GLM/L
MH;F&`[#*SD98=<8[=JU5.Z,G4L[&7_PN6_\`^@1;_P#?QJ?LO,/:^0?\+EO_
M`/H$6_\`W\:CV7F'M?(/^%RW_P#T"+?_`+^-1[+S#VOD'_"Y;_\`Z!%O_P!_
M&H]EYA[7R&+\8+Q)'D71K8.^-Q\QN<=*7L@]KY%J#XR%SLO=%4QG@^7+V^A%
M/V0*J=UX?\9Z+XD^2SN=ESC)@E&U_P`/7\*S<6BU)/8P/&?Q`NO"NLI806$,
MT9A#[F8@C)/''TIQAS(4I\K*/A[XL#4=8BL]2LXK2&7Y5E5R0K=LY[53IV6@
ME4NSTVLC0X[QUXSN/"7V+R+2.X^T;L[V(QC'I]:N$.9$2ERF'X<^*%YKGB&S
MTV33H(DG8J75R2."?Z53IV5Q*I=V.I\:^*/^$5T5;J.-);F60)%&^<'N3QZ"
MHC'F94I<J//?^%QZM_T#;/\`\>_QK7V:,_:L]6T/58M;T2TU&(8$\88K_=;N
M/P.:Q:L[&J=U<Y?QKXSU7PG>1;--AGLIQ^[E+D$,.JFJC%2ZDRER]#`T[XPR
M3:C!%?:=%#:NVV21')*#UJG3)534]65E=0RL&4C((.0161J>:^)/BJ=*UN>Q
MT^RBN8H/D:1G(R_<#'8=*U5.Z,W4L[$WA?XA:KXCU)H5TJ%+:!#)/(K,2JCL
M!W)[4G!16X1GS/8Z31O$,^HWYMY[=$#J6C*$]!C\QSU]14N-BTSH:D9QOQ1_
MY$6Z_P"ND?\`Z$*TI_$14^$\#K<YSIO`_B5O#/B".9V/V.?$=PO^SV;\.OYU
M,XW1<)<K/5_B!XK30O#P6TE!O+U=L)4_=7'+_KQ]:QA&[-9RLCP/J<FN@YQ\
M$7GW$4(.W>P7/IDT`>E_\*9O/^@Q#_WY/^-9>T1K[+S#_A3-Y_T&(?\`OR?\
M:/:(/9>9YWJ=B=,U2ZL6D$C6\K1E@,`X.,UJ9M6=C>\*^![WQ7:W$]K=00K`
MX0B3.22,]A4RFHE1AS*Y9UKX9Z_H]L]R$BNX4&6,!)('KM(!_*DII@Z;1R,$
M\MM.DT$C1RQG<KJ<$&K(.G\37LWB32;'Q`Y!FB`L[I0.CC)5_HPS^(-3%<NA
M<GS*YRE40>U?#3QG_:MJ-&U"3-[`O[IV/^M0=OJ/Y5C.-M4;PE?1F9\9_P#F
M$?\`;3_V6JI;,FKT.-^'_P#R/6E?]=#_`.@FJG\+(A\1I?%#7/[5\4-:Q-F"
MQ'E#'=_XC_3\*4(V151W=CB<<9JS,]8^#^N?)=Z)*_(_?P@_DP_D?SK*HNIM
M3?0]"\0:);>(=&GTZY&`XRC]T8=&%9)V=S1JZL?-^I:=<Z3J,]C=ILGA8JP_
MJ/:NI.ZN<S5G8[32_B//8>!IM*)<ZA'^ZMI?[J'O]5Z#ZCTK-P]ZY:G:-CA8
M()KNYC@A1I)I6"JHY+$UI<S/HGP?X:B\,:%':##7+_/.X_B;T^@Z"N>4N9G3
M&/*K&O;:?9V<CR6]M'$[]2JXXZX^GM4W*+-(#C?BC_R(MU_UTC_]"%:4_B(J
M?">!UN<YHZUHUSH6HM9W(R=H='`X=2,@BDG<;5F5KF]N;P0BYF>7R8Q%'N.=
MJCH!3V$W<M:AHMSINFZ=>7`V_;E9XT/4*"`"?KFDG<;5D4(Y&BE21#AD(8?4
M4Q'4_P#"RO%?_02'_?E/\*7+'L7SR+>F?$3Q1<:K9PR:B#'),BL/*3D%@#VI
M.$;;#4Y7.?\`%/\`R->K?]?4G_H1JELB);L],^#7_('U/_KNO_H-85-S:GL>
MEUF:'SGXZL(=,\9ZE;VZA(MX=57HNX!L?K73%W1S35F/\/?O?#7B:W;[GV:.
M8`]F60`'\F-#W0X[,R-.TJZU070M$\Q[>(S,HZE01G'YU3=B4KE>UN9K*ZBN
M;:1HYHF#(RG!!%`EH=?XT\4P^*=%T:?A+R'>EQ&.S?+R/8U,5RW1<I<R1SN@
M:G_8NM0:B!N:`,RCU;:0/U--JZL3%V=S/D=YI6D=BTCL22>I)I["/2?%'@S^
MSOAQIEPD8%U:?/<D#DB3KGZ'`K.,KR-90M$X;P_JTFA:[9ZC&3^Y<%@#]Y>A
M'Y9JVKJQG%V=SZ8AFCN((YHFW1R*'4CN",BN4ZCSCXM:!:S:6FMJZ17,)$;`
M\>:IZ#ZC^6:UIO6QG46ESQNMC`]2^$>@6L\MQK4TB230-Y<47>,D<L?J.!^-
M95';0VII;GKE8FH4`%`'&_%'_D1;K_KI'_Z$*TI_$14^$\#K<YSW7QIX5_X2
M+PG;36R9O[2$/'@<NNWE/\/?ZUA&7*SHE&Z/-/`GA9O$FO*LR$6-MAYSCKZ+
M^/\`+-:SERHRA&[.E^,BK'=Z.B*%58G``&`!E:BEL55Z'FUI&LMY!&XRKR*I
M^A-;&1[M_P`*N\*_\^<O_?\`;_&N?VDCH]G$D@^&GAFVN(IXK2421,'4^<QP
M0<CO2]HPY(H\6\4_\C7JW_7U)_Z$:Z%LC"6[/2?@[(D>CZD'=5_?KU./X:QJ
M+4VI[';:SXHT?0K5YKR]B#`<1(P9V/H!4*+9;:6Y\\ZWJLNMZS=ZC,-K3N6V
MY^Z.P_`8KI2LK',W=W-2Q_XEO@?4;A^'U*5+:$>JH=SGZ9VBEU&M(FY\(?\`
MD;)_^O5O_0EJ*FQ5/<7XD^#/[&O#JUA'BPG;]XH'^J<_T-$)7T83C;5'GU:&
M84`2V\S6US%.@4O&P=0PR,@YZ4`M#I[SXC>([^RFL[FXA>"9"CKY"\@_A4J"
M3N6YMG)U1![E\+-=&H>&6L9G'G:>=O)_Y9GE3_,?A6%16=SHINZ//OB%XK/B
M+6?(MGSI]H2L6/XV[M_A[5I"-D93E=V.76PNGT][]8'-HD@C:4#@,1D"KOT(
ML[7-?P=XEE\,:['=<M:R?)<(/XE]?J.M3*-T5&7*SZ*@GBN;>.>"19(I%#(R
MG@@]#7-L=))0`4`<;\4?^1%NO^ND?_H0K2G\1%3X3P.MSG/J:P_Y!UK_`-<E
M_D*Y7N=8VQTVSTT3BSMTA\^4RR;1]YCU-#;>X)6/*_C-_P`?VD_]<Y/YBM:6
MQC5Z'F`)!R.#6QD3?;;K_GYE_P"^S2L.[#[;=?\`/S+_`-]FBP79"S%F+,22
M>I-`A0[*,!B/H:`$Y8]R33`Z_P`+_#S5M?FCEN(GLK#.6ED7#,/]D'K]>E9R
MFD7&#9/\3K2'3=<LM/M1LMK>T58TST&3S]313=T.IHTBQ\(?^1MG'_3JW_H2
MTJFP4]SVF[M(+ZSEM+F-9()5*NK="#6&QN?/'C#PO/X6UAK=LO:R?-!*?XE]
M#[BNF,N9'-*/*SGJHD]0\!?#_3M:T`ZCJT4I,LA$(5RORCC/YY_*LIS:=D;0
M@FM3J?\`A5?A?_GWG_[_`!J.>17)$\[^(GA&W\,WUK)8(XLKA"/F;=AQU&?H
M1^M:PE?<SG%1V.6L-5O-,2Z6TG:(7,1ADQW4GD?I5M7(3:V$TS3KG5M2@L+1
M-\\S!5'I[GV%#=E<$KNQ]#6OA/3K;PG_`,(^4WV[1E7;NS'JWUSS^`KF<G>Y
MT**2L?/^NZ-<:#K%QIUR/GB;Y6[.O9A]170G=7.=JSL>B_"KQ9M/_"/7LG!R
MUJS'\2G]1^-9U(]36G+H>L5B:A0!2U2/3I;/R=3CADMG8#;,H*D]1U^E'-RA
M:^A0D\.>&8WCCDTFQ!E.$!A7YOTI\[#E78UA-!#+':AU60KE(_84KCL5GUK3
MHG='NXPR'##T-*Z'ROL17-KHNLR+]IM[:[:)-P,B!MJGGO34NQ+7<H0Z3X1N
M)A#%8:>\AZ`1+S].*/:>8<ENA/'X=\,RRR11Z58L\1PZB)<K3YGW#E2Z"1^'
MO#,L+3)I5B8USEO)7`QUHYWW#E2Z"#0/##6GVH:78F#&[?Y(QC\J.=VO<.6S
MM8E3POX>=%=='LBK#(/DKR*?,Q61-;:9HEC=+#;6-I!<;=X"1*&QZ]*EROHV
M-*VQ<DO+:*1XWF571-[#T7UI72'8R;A/#6K7:M<PVEU<$;07C#-@<XZ?6J4K
M;`X]T+ID7ANUO,Z;#9PW##;F-`K$>E+GOU#D:UL:XN83-)")%\R,!G']T&E<
M+&=</H>LLEK<BUNR#E4D4-S[9IJ79@XOJB%O#OAI;E;<Z58B9AN5?)7)%/G>
MUQ<JWL:=M]DML6%LL<0A08B08"KVXI7U':R+-`C)O)="U-EM+TVUSM?Y4D`8
M!O;/&:2FD]&-Q=MBA+IG@^&9H9+'3UD4X(,0X/Y57/YAR>1>BT[0-&9;V&TL
M[5B-JRH@!(/H12<M-6)1UT1=34;.2U>Y2X0PI]Y@>GUI70[.]BMJ&FZ->O%<
M:A9VTS'"(\L88\]!FJYK"M<SX]/\)17:!+.PCN(WRI\L`JP]\<&CG\Q\G6QT
M=(04`8OB95>RMD895KA0?R-9S5[(N&ERH1/::II]E<$ND3LT4I/5,=#[BIV:
M3'NFRM,]U<SRZG%:2N4D#0R`@`(O;'OS2=W[PU9:&G.T%UJNCS(BE)1(W3K\
MHZU;U:)6B95U)'-SJJQ*21%%E5_N]_TJ9+5C70DU&?3KC3(HK(QF<E?(6,?,
MIS^E.336@1NGJ1I#.NI7]]:G,L$N'C[.N.1]?2FUJY($]$F01W#OH,-K;HSR
M7,K_`"KUV`Y-0G[MD/:5V21R/;66HV,D#0*T32PHYS@="*:T30;V9LZ??VDD
M%O"EQ&TNP#8&YX%:1:L0TT9VIV\USKZBW?9/#;>9&?4[L8J)*\M"D[1*<EO+
M;7-Z;A]UQ+8M)(>P);H/IBE:S=^P[W2+>GSDB-'O;)U\O`C1</G''.>M5&UM
M&3)=;%99[!_#4<!*/=%<(B\ONSQ4JW)8K7FN+=).3J2$%I1##Y@'4@?>H?42
ML::WNB[;;8T)P1Y84<I_A5WAH*TC&EDNKB5]5BM)25</')D8$:\8Q[\UGJ_>
M2*T6AIQWULNNO</,B1R6RE2Q`SS5)KFN39VL7[YS<Z1.UH^\M&=I4]?I6CU6
M@EH]3#EO(8=+MVLS9E$5<PR+F0OGGCUK-RLE8OE=]197NHI=6DM[>&6-9#OW
MC+#CL*&VFVA)+0?;K:V=Y8M<2+);?9\0RL/E#YR?I0K)H;NTQEZ([N?4'T\!
MHA;_`+TH.&;.?Q.*3U;L"T2N6;N]M[VWTZ&WE625IHVV@\@#KGTIMIV2)2:W
M*T-M>7L%W;PP6YA>=P97/S+SV%"5TRFTK,Z:)/+B1,D[5`R>]:+0S'4Q#7C2
M0`.BL`<C<,X-%AB/%')CS(U?'3<,XI6N`Y45$"*H"@8``XIB&+!$FS;$@V9V
MX4?+GKCTI60QP1`Y<(`YZG')IB&);012&2."-'/5E4`FE9(=QZHB%BJ!2QR2
M!C-,!JP0QON2)%;U"@&E9(!7ABD(,D:.0,`LH/%.P#$M+:)P\=O$C#H50`BE
M9(&VR38GF;]HWXQNQSCTIB$:&)V+-&K$KM)*YR/3Z46&,6SM48,MM$K#H0@%
M*R078L=M;Q-NC@C1O55`-%D@;;W'B-%<N$4.>K8Y-,"-;2V1F9;>)6<88A`"
M?K2LD%V2JBH@15`4#``'`I@0FRM#C-M"<<#Y!Q2Y5V'=DJ(D:!$4(HZ!1@"G
ML(9]F@$WG""/S?[^T;OSI66X7>P\1HI8JB@MRV!U^M,!AMH##Y)AC\K^YM&/
MRI66P7'QQ1PH$B140=%48`I[`,CMH(I#)'!&CGJRJ`32LD%V/2-(P0B*H)R<
*#'-,!U`@H`__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
